An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum
Great news!
Our paper “Data infrastructures for AI in medical imaging: a report on the experiences of five EU projects” published in European Radiology Experimental, has been the Fourth most cited article for the Impact Factor 2024 calculation. A short award ceremony will take place during the ECR 2026 in Vienna in March,to acknowledge the certificate.
An international and multidisciplinary team, led by researchers from the Champalimaud Foundation, in Lisbon, has developed an artificial intelligence algorithm that improves the reliability of prostate cancer detection based solely on magnetic resonance imaging...
Prostate cancer is the second most commonly diagnosed cancer in men. Conventional screening relies on prostate specific antigen (PSA) levels in the blood, which can indicate prostate abnormalities but lacks specificity. Clinical examination and ultrasound also have...
The ProCAncer-I project aims to revolutionize prostate cancer diagnosis and treatment through the power of artificial intelligence and advanced imaging. By creating a large, federated database of prostate MRI scans and clinical data, the project enables the...
ProCAncer-I results | Prof. Daniele Regge on clinical validation In this video, we present the results of the clinical validation of AI models that were developed during the ProCAncer-i Project. Clinical validation is a critical step to ensure that AI tools not only...